Scientists at the University of Bristol have invented a new technology that could lead to the development of a new generation of smart surgical glues and dressings for chronic wounds. The new method, pioneered by Dr Adam Perriman and colleagues, involves re-engineering the membranes of stem cells to effectively “weld” the cells together.
The University of Bristol and Max Planck Society will be presenting their new ground-breaking research collaboration at the BUILA/DAIA Showcase at the British Embassy in Berlin today [Tuesday 14 May].
A University of Bristol scientist who helped develop a key breakthrough in binding glucose which could lead to improved treatment for people with diabetes has been awarded the 2025 Royal Medal for Applied Sciences from the Royal Society.
A new gene therapy approach aimed at protecting people with type 1 diabetes from developing diabetic kidney disease — a serious and common complication of the condition, has shown promising results in a University of Bristol study.
Rosa Biotech, a new University of Bristol spin-out which developed a sensing platform capable of detecting the faint chemical signature given off by chronic diseases has raised £760,000 to commercialise its ground-breaking innovation. The artificial Intelligence (AI)-driven biosensing technology, which mimics mammals’ sense of smell, has significant potential to transform the medical diagnostics and pharmaceuticals industries.
A University of Bristol spin-out company has raised £1.1 million in funding to develop next generation cell therapies that could open new ways to treat solid tumours and improve the lives of 18 million people worldwide who are diagnosed with cancer each year.
A new type of vaccine that can be stored at warmer temperatures, removing the need for refrigeration, has been developed for mosquito-borne virus Chikungunya in a major advance in vaccine technology. The findings, published in Science Advances today [Wednesday 25 September], reveal exceptionally promising results for the Chikungunya vaccine candidate, which has been engineered using a synthetic protein scaffold that could revolutionise the way vaccines are designed, produced and stored.
Researchers at the University of Bristol and Imperial College London have established a new model system that uses red blood cells grown in the laboratory to study how malaria parasites invade red blood cells.
World-leading vaccine scientists from the University of Bristol are working with one of Vietnam's major vaccine manufacturers, Vabiotech, to share cutting-edge knowledge that could help prevent future global outbreaks of avian flu and rabies.
University of Bristol spin-out, Rosa Biotech, was named as one of the most exciting health chemistry innovators in Europe after winning a Royal Society of Chemistry (RSC) Emerging Technologies 2019 award for its biosensing platform that mimics the mammalian olfactory (smelling) system. Rosa was one of two innovations to win the award and a share of £80,000 prize.
